Second Chance for Cure: Stereotactic Ablative Radiotherapy in Oligometastatic Disease

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Oligometastatic disease represents an intermediate state between localized cancer and widely metastatic disease.
• Local ablative therapies, including surgery and radiotherapy, are increasingly explored for managing oligometastases.
• Stereotactic ablative body radiotherapy (SABR) offers a precise, high-dose radiation approach for limited metastatic burden, even in challenging locations.

Purpose of the Study:

• To evaluate the efficacy of metastatic-directed therapy using SABR in patients with oligometastases.
• To determine the impact of SABR on progression-free survival (PFS) and overall survival (OS).
• To investigate whether the primary tumor site or metastatic site influences patient outcomes.

Main Methods:

• Retrospective, single-arm, observational study of 60 patients with controlled primary tumors and 1-5 metastases treated with SABR.
• Radiation doses ranged from 12 to 60 Gy in 1-7 fractions.
• Data collected and analyzed for PFS, OS, and time to first progression.

Main Results:

• The most common primary cancers were prostate, colorectal, lung, and breast.
• 1-, 3-, and 5-year PFS rates were 54.9%, 37.0%, 37.0%, and OS rates were 98.3%, 84.4%, 73.8%, respectively.
• Primary tumor site was not an independent prognostic factor; localized bone and liver metastases may influence outcomes.

Conclusions:

• SABR demonstrated favorable PFS and OS in patients with oligometastases in this retrospective analysis.
• The findings suggest SABR is a viable option for metastatic-directed therapy.
• High-level evidence and randomized controlled trials comparing SABR with standard palliative care are essential.